Robin Parihar, M.D., Ph.D.
Picture

Robin Parihar, M.D., Ph.D.
Assistant Professor
Positions
- Assistant Professor
-
Pediatrics
Hematology-Oncology
草榴社区入口
Houston, Texas
- Associate Director
-
Pediatric Hematology/Oncology Fellowship Program
草榴社区入口
Houston, Texas
- Faculty Member
-
Center for Cell and Gene Therapy
草榴社区入口
Houston, Texas
- Research Member
-
Dan L Duncan Comprehensive Cancer Center
草榴社区入口
Houston, Texas
- Faculty Member
-
Immunology and Microbiology
Graduate School of Biomedical Sciences
草榴社区入口
Houston, Texas
- Faculty Member
-
Development, Disease Models, and Therapeutics
Graduate School of Biomedical Sciences
草榴社区入口
Houston, Texas
Addresses
- Texas Children's Hospital, Mark Wallace Tower (Clinic)
-
6701 Fannin St
14th floor
Houston, TX 77030
United States
Phone: (832) 822-4242
Certifications
- Board Certified
- American Board of Pediatrics
- Pediatric Hematology-Oncology
- Fellow (FAAP)
- American Academy of Pediatrics
- Board Certified
- American Board of Pediatrics
- General Pediatrics
Professional Interests
- Pediatric solid tumors
- Solid tumor microenvironment
- Natural Killer (NK) cell biology
- Cellular therapies for solid tumors
Professional Statement
I am a pediatric oncologist with an interest in caring for children with solid tumors. I have an active research lab interested in stimulating the immune system to fight solid tumors. My lab investigates the role of a specific type of immune cell called the natural killer (NK) cell in the control of cancer. My current research projects aim to enhance NK cell function in order to target the tumor microenvironment, essentially getting rid of the accessory cells that help a tumor resist standard therapies. I am currently working on introducing the enhanced NK cells as therapy for children with advanced cancers. In addition, we are using our established lab models to better understand how the tumor microenvironment suppresses the immune system, in order to develop new approaches to overcome this inhibition and improve immune-based therapies for pediatric cancers.Websites
Selected Publications
- Navin, I., Lam, M.T., and Parihar, R. "." Cancers. 2020 Dec 21;12(12):3871-79.. Pubmed PMID:
- Devkota, L., Starosolski, Z., Rivas, C.H., Stupin, I., Annapragada, A., Ghaghada, K.B., and Parihar, R. "." Science Advances. 2020 Jul 10;6(eaba6156.) Pubmed PMID:
- Dysthe, M., and Parihar, R. "." Adv. Exp. Med. Biol.. 2020;1224:117-40. Pubmed PMID:
- Parihar, R., Rivas, C., Huyhn, M., Omer, B., Lapteva, N., Metelitsa, L., Gottschalk, S., and Rooney, C.M. "." Cancer Immunology Research. 2019;7(3):363-75.. Pubmed PMID:
- Lapteva, N., Parihar, R., Rollins, L.A., Gee, A.P., and Rooney, C.M. "." Methods Molec. Biol.. 2016;1441:195-202. Pubmed PMID:
to edit your profile